cms.bioaccessla.com

Author: Julio Martinez-Clark

  • STEER vs a First-in-Human Device CRO (bioaccess®)

    If you typed STEER into a search box, you are probably building a CRO or site shortlist for Ecuador. This article uses only what is public about STEER (ARCSA register of contract research organizations) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What STEER publishes

    STEER Centro de Administración y Asesoría en Investigación Clínica Cía. Ltda. is a Quito-based company listed in the national register of contract research organizations kept by Ecuador’s regulator ARCSA.

    STEER vs bioaccess®

    Dimension STEER bioaccess®
    Core focus Clinical research administration, Ecuador First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need an ARCSA-registered local organization for clinical research administration in Ecuador, STEER’s registration matches.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO or site on your list, including STEER, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    For the local regulatory path, see CRO in Ecuador. Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Facts from the STEER public pages and registries linked above, reviewed for bioaccess® competitive research (Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • TRIAL (Therapeutic Research Institute and Lab) vs a First-in-Human Device CRO (bioaccess®)

    If you typed TRIAL (Therapeutic Research Institute and Lab) into a search box, you are probably building a CRO or site shortlist for Guatemala. This article uses only what is public about TRIAL (trialresearch.org) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What TRIAL publishes

    TRIAL describes itself as a CRO and site management organization (SMO) in Guatemala, offering regulatory services, investigational product management including storage and distribution, research site support and continuing education.

    TRIAL vs bioaccess®

    Dimension TRIAL bioaccess®
    Core focus CRO/SMO, regulatory and logistics, Guatemala First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need a Guatemala-based CRO/SMO for regulatory, logistics and site support, TRIAL’s published services match.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO or site on your list, including TRIAL, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    For the local regulatory path, see CRO in Guatemala. Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Facts from the TRIAL public pages and registries linked above, reviewed for bioaccess® competitive research (Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • ICIC (Instituto Costarricense de Investigaciones Clínicas) vs a First-in-Human Device CRO (bioaccess®)

    If you typed ICIC (Instituto Costarricense de Investigaciones Clínicas) into a search box, you are probably building a CRO or site shortlist for Costa Rica. This article uses only what is public about ICIC (ClinicalTrials.gov NCT04497610) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What ICIC publishes

    The Instituto Costarricense de Investigaciones Clínicas (ICIC) is a clinical research institution in San José, Costa Rica. It is the lead sponsor on ClinicalTrials.gov of a study of a breath-analyzer system for SARS-CoV-2 detection (NCT04497610).

    ICIC vs bioaccess®

    Dimension ICIC bioaccess®
    Core focus Clinical research institution, Costa Rica First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need a clinical research institution in Costa Rica, ICIC’s public record matches.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO or site on your list, including ICIC, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    For the local regulatory path, see CRO in Costa Rica. Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Facts from the ICIC public pages and registries linked above, reviewed for bioaccess® competitive research (Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • QPharma Research vs a First-in-Human Device CRO (bioaccess®)

    If you typed QPharma Research into a search box, you are probably building a CRO or site shortlist for Dominican Republic. This article uses only what is public about QPharma Research (qpharmaresearch.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What QPharma Research publishes

    QPharma Research describes itself as a Caribbean research partner based in the Dominican Republic, focused on delivering human biospecimens (tissue, FFPE, blood and other samples) with clinical data for research, through prospective and archived collections.

    QPharma Research vs bioaccess®

    Dimension QPharma Research bioaccess®
    Core focus Biospecimens and research support, Caribbean First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need human biospecimens or research support in the Caribbean, QPharma’s published services match.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO or site on your list, including QPharma Research, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    For the local regulatory path, see CRO in Dominican Republic. Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Facts from the QPharma Research public pages and registries linked above, reviewed for bioaccess® competitive research (Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • VaxTrials (now Emmes) vs a First-in-Human Device CRO (bioaccess®)

    If you typed VaxTrials (now Emmes) into a search box, you are probably building a CRO or site shortlist for Panama. This article uses only what is public about VaxTrials (Emmes announcement) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What VaxTrials publishes

    VaxTRIALS was a Panama City-based CRO specializing in vaccine trials in Latin America and the Philippines; Emmes announced its acquisition in 2023. Vaxtrials S.A. appears on ClinicalTrials.gov as sponsor or collaborator on polio vaccine studies supported by the Gates Foundation (e.g. NCT02111135).

    VaxTrials vs bioaccess®

    Dimension VaxTrials bioaccess®
    Core focus Vaccine and infectious-disease trials (part of Emmes) First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need vaccine or infectious-disease trial capacity in Latin America, Emmes/VaxTRIALS’ public record matches.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO or site on your list, including VaxTrials, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    For the local regulatory path, see CRO in Panama. Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Facts from the VaxTrials public pages and registries linked above, reviewed for bioaccess® competitive research (Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Endpoints LatAm vs a First-in-Human Device CRO (bioaccess®)

    If you typed Endpoints LatAm into a search box, you are probably building a CRO or site shortlist for Panama. This article uses only what is public about Endpoints LatAm (www.endpoints.site) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Endpoints LatAm publishes

    Endpoints LatAm describes itself as a Panama-based clinical research site network serving sponsors, CROs and NGOs, with centers in Panama, Colombia and Guatemala and expansion across Latin America.

    Endpoints LatAm vs bioaccess®

    Dimension Endpoints LatAm bioaccess®
    Core focus Multi-country clinical site network First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need access to a multi-country research site network in Latin America, Endpoints LatAm’s published services match.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO or site on your list, including Endpoints LatAm, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    For the local regulatory path, see CRO in Panama. Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Facts from the Endpoints LatAm public pages and registries linked above, reviewed for bioaccess® competitive research (Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • BOPAL vs a First-in-Human Device CRO (bioaccess®)

    If you typed BOPAL into a search box, you are probably building a CRO shortlist. This article uses only what BOPAL publishes (www.bopalcro.com · bopalcro.com/es) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What BOPAL publishes

    BOPAL is a Santiago, Chile, contract research organization and regulatory affairs consultancy founded in 2019 by Pablo García, its CEO and a former regulatory manager of the clinical studies unit at Sanofi Chile. It serves the pharmaceutical and biotechnology industry with Phase I–IV trials and lists clinical operations, importer-of-record support for clinical trials, statistics, medical writing, data management, real-world evidence and 24/7 pharmacovigilance. It says it ran Chile's largest COVID-19 vaccine trial, with 3,500 volunteers, and Chile's first trial of an inhaled COVID-19 vaccine. Its regulatory practice includes acting as technical director before Chile's ISP and managing imports with the ISP. The site mentions medical devices only in the founder's background.

    BOPAL vs bioaccess®

    Dimension BOPAL bioaccess®
    Core focus Chile drug and vaccine CRO plus regulatory consultancy First-in-human and early feasibility studies for medical devices
    Geography Chile HQ (Santiago); CRO partners in the US, Mexico, Argentina, Peru and Colombia Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial Sanitary registration (pharma, bioequivalents, cosmetics), technical direction before ISP and 24/7 pharmacovigilance Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need a Chile-based CRO for a drug or vaccine study, with ISP regulatory and pharmacovigilance support from the same firm, BOPAL publishes that menu.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including BOPAL, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Competitor facts from the BOPAL public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug 2026–Nov 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Prospective Research Services (PRS) vs a First-in-Human Device CRO (bioaccess®)

    If you typed Prospective Research Services (PRS) into a search box, you are probably building a CRO or site shortlist for Chile. This article uses only what is public about Prospective Research Services (www.prs.cl) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Prospective Research Services publishes

    PRS describes itself as a Chilean contract research organization established in 2014 that offers a broad range of services to support clinical studies in Chile.

    Prospective Research Services vs bioaccess®

    Dimension Prospective Research Services bioaccess®
    Core focus Clinical operations, Chile First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need a Chile-based team for study operations, PRS’s published services match.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO or site on your list, including Prospective Research Services, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    For the local regulatory path, see CRO in Chile. Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Facts from the Prospective Research Services public pages and registries linked above, reviewed for bioaccess® competitive research (Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • Thera Research vs a First-in-Human Device CRO (bioaccess®)

    If you typed Thera Research into a search box, you are probably building a CRO or site shortlist for Chile. This article uses only what is public about Thera Research (theraresearch.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What Thera Research publishes

    Thera Research Ltda. is a Santiago, Chile-based CRO. Its public pages describe site identification, feasibility, regulatory submissions to Chile’s ISP, monitoring, data management, medical writing, biostatistics and safety support for Phase I–IV studies.

    Thera Research vs bioaccess®

    Dimension Thera Research bioaccess®
    Core focus Drug CRO and local representation, Chile First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need a Chile-based CRO for ISP submissions and monitoring, Thera Research’s published services match.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO or site on your list, including Thera Research, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    For the local regulatory path, see CRO in Chile. Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Facts from the Thera Research public pages and registries linked above, reviewed for bioaccess® competitive research (Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.

  • ReSolution Latin America vs a First-in-Human Device CRO (bioaccess®)

    If you typed ReSolution Latin America into a search box, you are probably building a CRO or site shortlist for Argentina. This article uses only what is public about ReSolution Latin America (LinkedIn company page) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.

    What ReSolution Latin America publishes

    ReSolution Latin America is an Argentina-based clinical research company. On ClinicalTrials.gov it is a listed collaborator on studies for Syntara (inhaled mannitol, NCT00630812) and Revimmune (interleukin-7, NCT04927169).

    ReSolution Latin America vs bioaccess®

    Dimension ReSolution Latin America bioaccess®
    Core focus Clinical operations for foreign sponsors First-in-human and early feasibility studies for medical devices
    Geography See provider site Latin America, since 2010
    Device FIH track record No named device first-in-human study found on the public pages reviewed Published case studies on bioaccessla.com
    After the trial See provider site Live multi-country sanitary registration and in-country holder service

    Where each one fits

    If you need Latin American clinical operations for a drug study, ReSolution’s public record matches.

    If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO or site on your list, including ReSolution Latin America, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.

    For the local regulatory path, see CRO in Argentina. Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.

    Ready to compare a proposal? Request a first-in-human study proposal.

    Facts from the ReSolution Latin America public pages and registries linked above, reviewed for bioaccess® competitive research (Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.